RBC Life Science & Technology Fund A (RBF274)
30.56
+0.06 (+0.18%)
CAD |
Jan 27 2023
Returns Chart
Key Stats
Customize
| Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
|---|---|---|---|
| 2.05% | 1.037B | 0.00% | 16.80% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
| -37.54M | -7.33% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The fund invests primarily in equity securities of U.S. companies whose businesses relate to life sciences and technology and are expected to benefit from scientific and technological advances. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | RBF274 |
| Equity Style | Large Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | US Equity |
| Category Index | Morningstar US Market GR CAD |
| Global Category Name | US Equity Large Cap Blend |
| YCharts Categorization | US Large Cap Blend |
| YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
| Prospectus Objective | -- |
| Fund Owner Firm Name | RBC Global Asset Management Inc. |
| Prospectus Benchmark Index | |
| S&P 500 TR CAD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Marcello Montanari | 6.09 yrs |
| Rob Cavallo | 6.09 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
86
-37.54M
-1.795B
Category Low
2.824B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of December 31, 2022
Performance Versus Category
As of January 27, 2023. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of January 27, 2023.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
|
Microsoft Corp
|
10.43% | -- | -- |
| Apple Inc | 9.29% | 145.93 | 1.37% |
|
Alphabet Inc Class A
|
7.39% | -- | -- |
|
UnitedHealth Group Inc
|
4.04% | -- | -- |
|
Visa Inc Class A
|
2.91% | -- | -- |
|
Johnson & Johnson
|
2.64% | -- | -- |
| Mastercard Inc Class A | 2.62% | 374.03 | -0.85% |
| NVIDIA Corp | 2.48% | 203.65 | 2.84% |
|
Eli Lilly and Co
|
2.22% | -- | -- |
|
Merck & Co Inc
|
2.20% | -- | -- |
Basic Info
| Investment Strategy | |
| The fund invests primarily in equity securities of U.S. companies whose businesses relate to life sciences and technology and are expected to benefit from scientific and technological advances. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | RBF274 |
| Equity Style | Large Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | US Equity |
| Category Index | Morningstar US Market GR CAD |
| Global Category Name | US Equity Large Cap Blend |
| YCharts Categorization | US Large Cap Blend |
| YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
| Prospectus Objective | -- |
| Fund Owner Firm Name | RBC Global Asset Management Inc. |
| Prospectus Benchmark Index | |
| S&P 500 TR CAD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Marcello Montanari | 6.09 yrs |
| Rob Cavallo | 6.09 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (1-27-23) | 0.00% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 23.71 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of December 31, 2022
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 7/31/1995 |
| Last Annual Report Date | 12/31/2021 |
| Last Prospectus Date | -- |
| Share Classes | |
| RBF1030 | Do-It-Yourself |
| RBF619 | Fee-based Advice |
| RBF8274 | Institutional |
| Attributes | |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |